JPWO2020264269A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020264269A5 JPWO2020264269A5 JP2021576970A JP2021576970A JPWO2020264269A5 JP WO2020264269 A5 JPWO2020264269 A5 JP WO2020264269A5 JP 2021576970 A JP2021576970 A JP 2021576970A JP 2021576970 A JP2021576970 A JP 2021576970A JP WO2020264269 A5 JPWO2020264269 A5 JP WO2020264269A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- polypeptide chain
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 193
- 125000003275 alpha amino acid group Chemical group 0.000 claims 191
- 229920001184 polypeptide Polymers 0.000 claims 190
- 102000004196 processed proteins & peptides Human genes 0.000 claims 190
- 210000004027 cell Anatomy 0.000 claims 23
- 108091008874 T cell receptors Proteins 0.000 claims 21
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 21
- 150000007523 nucleic acids Chemical class 0.000 claims 14
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 102000004169 proteins and genes Human genes 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 239000013604 expression vector Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 238000003259 recombinant expression Methods 0.000 claims 7
- 241000124008 Mammalia Species 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 239000013598 vector Substances 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000037828 epithelial carcinoma Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 210000000581 natural killer T-cell Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025020882A JP2025081413A (ja) | 2019-06-27 | 2025-02-12 | ｐ５３におけるＲ１７５Ｈ又はＹ２２０Ｃ変異を認識するＴ細胞受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962867619P | 2019-06-27 | 2019-06-27 | |
| US62/867,619 | 2019-06-27 | ||
| PCT/US2020/039785 WO2020264269A1 (en) | 2019-06-27 | 2020-06-26 | T cell receptors recognizing r175h or y220c mutation in p53 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025020882A Division JP2025081413A (ja) | 2019-06-27 | 2025-02-12 | ｐ５３におけるＲ１７５Ｈ又はＹ２２０Ｃ変異を認識するＴ細胞受容体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022538148A JP2022538148A (ja) | 2022-08-31 |
| JPWO2020264269A5 true JPWO2020264269A5 (https=) | 2023-06-29 |
| JP2022538148A5 JP2022538148A5 (https=) | 2023-06-29 |
| JP7635165B2 JP7635165B2 (ja) | 2025-02-25 |
Family
ID=71662353
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021576970A Active JP7635165B2 (ja) | 2019-06-27 | 2020-06-26 | ｐ５３におけるＲ１７５Ｈ又はＹ２２０Ｃ変異を認識するＴ細胞受容体 |
| JP2025020882A Pending JP2025081413A (ja) | 2019-06-27 | 2025-02-12 | ｐ５３におけるＲ１７５Ｈ又はＹ２２０Ｃ変異を認識するＴ細胞受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025020882A Pending JP2025081413A (ja) | 2019-06-27 | 2025-02-12 | ｐ５３におけるＲ１７５Ｈ又はＹ２２０Ｃ変異を認識するＴ細胞受容体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12479902B2 (https=) |
| EP (1) | EP3990481A1 (https=) |
| JP (2) | JP7635165B2 (https=) |
| KR (1) | KR20220047969A (https=) |
| CN (1) | CN114341171A (https=) |
| AU (1) | AU2020308004B2 (https=) |
| BR (1) | BR112021026408A2 (https=) |
| CA (1) | CA3144070A1 (https=) |
| MX (1) | MX2021015877A (https=) |
| TW (2) | TWI908730B (https=) |
| WO (1) | WO2020264269A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210189336A1 (en) * | 2017-10-18 | 2021-06-24 | Vivia Biotech, S.L. | Bite-activated car-t cells |
| IL305393A (en) | 2021-02-25 | 2023-10-01 | Alaunos Therapeutics Inc | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| US20240209058A1 (en) * | 2021-04-30 | 2024-06-27 | Regents Of The University Of Minnesota | Mesothelin-specific T cell Receptors and Methods of Using Same |
| AU2022271195A1 (en) * | 2021-05-03 | 2023-11-02 | Bluesphere Bio, Inc. | T cell receptors (tcrs) targeting minor histocompatibility antigen ha-1 |
| WO2022236050A1 (en) * | 2021-05-07 | 2022-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing c135y, r175h, or m237i mutation in p53 |
| EP4423143A4 (en) * | 2021-10-29 | 2025-10-01 | Yafei Hou | T CELL RECEPTOR RECOGNIZING R175H MUTATION IN P53 AND ITS APPLICATION |
| US20250145950A1 (en) | 2022-02-01 | 2025-05-08 | Alaunos Therapeutics, Inc. | Methods for Activation and Expansion of T Cells |
| WO2024076692A1 (en) * | 2022-10-05 | 2024-04-11 | Icahn School Of Medicine At Mount Sinai | Heterobifunctional compounds as p53 acetylators |
| WO2024163371A1 (en) * | 2023-01-30 | 2024-08-08 | Fred Hutchinson Cancer Center | Binding proteins specific for mutant p53 and uses thereof |
| WO2024206274A2 (en) | 2023-03-27 | 2024-10-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting y220c or r175h mutation in p53 |
| WO2024220520A2 (en) * | 2023-04-21 | 2024-10-24 | Board Of Regents, The University Of Texas System | T-cell receptors targeting her2 and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003265948B8 (en) | 2002-09-06 | 2009-09-03 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| IL290655B2 (en) | 2014-05-29 | 2024-05-01 | Us Health | Anti-human papillomavirus 16 E7 T-cell chelates |
| CN107995913B (zh) | 2015-05-18 | 2022-02-11 | T细胞受体治疗公司 | 使用融合蛋白对tcr重编程的组合物和方法 |
| CN107748893A (zh) * | 2017-09-29 | 2018-03-02 | 阿里巴巴集团控股有限公司 | 提升车辆定损图像识别结果的方法、装置及服务器 |
| CA3080274A1 (en) * | 2017-09-29 | 2019-04-04 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation |
| EA202090757A1 (ru) | 2017-09-29 | 2020-08-21 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | T-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, РАСПОЗНАЮЩИЕ МУТАНТНЫЙ p53 |
| WO2022236050A1 (en) | 2021-05-07 | 2022-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing c135y, r175h, or m237i mutation in p53 |
| WO2024206274A2 (en) | 2023-03-27 | 2024-10-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting y220c or r175h mutation in p53 |
-
2020
- 2020-06-26 CA CA3144070A patent/CA3144070A1/en active Pending
- 2020-06-26 MX MX2021015877A patent/MX2021015877A/es unknown
- 2020-06-26 CN CN202080047882.0A patent/CN114341171A/zh active Pending
- 2020-06-26 US US17/620,942 patent/US12479902B2/en active Active
- 2020-06-26 WO PCT/US2020/039785 patent/WO2020264269A1/en not_active Ceased
- 2020-06-26 BR BR112021026408A patent/BR112021026408A2/pt unknown
- 2020-06-26 JP JP2021576970A patent/JP7635165B2/ja active Active
- 2020-06-26 TW TW109121744A patent/TWI908730B/zh active
- 2020-06-26 EP EP20742583.6A patent/EP3990481A1/en active Pending
- 2020-06-26 KR KR1020227002872A patent/KR20220047969A/ko active Pending
- 2020-06-26 AU AU2020308004A patent/AU2020308004B2/en active Active
- 2020-06-26 TW TW114110844A patent/TW202525841A/zh unknown
-
2025
- 2025-02-12 JP JP2025020882A patent/JP2025081413A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cafri et al. | mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer | |
| CN110809716B (zh) | 基于hla的方法和组合物及其用途 | |
| CN103570818B (zh) | 肿瘤抗原性多肽及其作为肿瘤疫苗的用途 | |
| ES2373055T3 (es) | Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno. | |
| JPWO2020264269A5 (https=) | ||
| WO2018085802A1 (en) | Methods for selecting therapy for a cancer patient | |
| CN115485368A (zh) | 通过单细胞分析从外周血分离t细胞和t细胞受体用于免疫治疗的方法 | |
| Tang et al. | A lncRNA Dleu2-encoded peptide relieves autoimmunity by facilitating Smad3-mediated Treg induction | |
| Zhang et al. | Global analysis of HLA-A2 restricted MAGE-A3 tumor antigen epitopes and corresponding TCRs in non-small cell lung cancer | |
| AU2020285380A1 (en) | Immunotherapy constructs targeting KRAS antigens | |
| IT202000006973A1 (it) | Antigeni herv tumore-specifici e loro uso nella immunoterapia del cancro | |
| EP3060679A1 (en) | Method and kit for determining whether a subject shows an immune response | |
| CN110464840A (zh) | 一种肿瘤疫苗的制备方法及使用该方法制备的肿瘤疫苗 | |
| JPWO2022236050A5 (https=) | ||
| CN116083368A (zh) | 基于tnfrsf9阳性t细胞的用于杀伤肿瘤的tcr-t细胞及其制备方法和应用 | |
| AU2024311891A1 (en) | Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy | |
| US20250057881A1 (en) | Compositions and methods for use of recombinant t cell receptors against claudin 6 | |
| US20240218019A1 (en) | Methods and compositions comprising mhc class i peptides | |
| RU2022101295A (ru) | T-клеточные рецепторы, распознающие мутацию r175h или y220c в p53 | |
| EP1930427B1 (en) | Squamous cell carcinoma antigen-derived peptide binding to hla-a24 molecule | |
| Engelhard | Direct identification of tumor-associated peptide antigens | |
| JPWO2022051449A5 (https=) | ||
| RU2840503C9 (ru) | Способ получения человеческого Т-клеточного рецептора, специфичного к эпитопу 112-120 (KVAELVHFL) рецептора MAGE-A3 | |
| CN116621946A (zh) | 多肽circ1946-109aa作为食管鳞癌预后标志物的应用 | |
| CN121944092A (zh) | 源自枯草芽孢杆菌的微生物多肽在制备抗肿瘤疫苗中的应用 |